Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2023 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
October 05, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting in AugustPermanent J-code effective as of October...
October 02, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Compact, single-use, on-body injector designed to enhance the patient experience of administering EMPAVELI® (pegcetacoplan) WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis...
September 25, 2023 07:30 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a...
September 06, 2023 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company...
September 05, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
August 30, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
August 29, 2023 06:58 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G Focusing research...
August 22, 2023 16:43 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in...
August 04, 2023 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...